[Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
Rheumatoid arthritis (RA) is characterized by inflammatory synovitis, erosive arthritis and joint destruction. Recent evidence indicates that inflammatory cytokines such as TNF-alphaor IL-6 plays a pathological role in joint destruction and osteoporosis and that anti-cytokine therapy provides significant protection against the process. In this article, we described our findings that TNF-alphablocking therapy decreased urinary crosslinked N-telopeptide of type I collagen and increased serum bone alkaline phosphatase in RA patients.
Okada
Yosuke
Y
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health.
Nawata
Masao
M
Tanaka
Yoshiya
Y
D000469:Alkaline Phosphatase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001842:Bone and Bones / Q000378:metabolism*; D024042:Collagen Type I / Q000652:urine; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D015850:Interleukin-6 / Q000502:physiology; D008727:Methotrexate / Q000627:therapeutic use; D010455:Peptides / Q000652:urine; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology; D000093242:Interleukin-6 Inhibitors
D000469:Alkaline Phosphatase; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D024042:Collagen Type I; D000069285:Infliximab; D015850:Interleukin-6; D008727:Methotrexate; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors; C052929:collagen type I trimeric cross-linked peptide